Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Latest updates in lymphoma trials

David Straus • 18 Aug 2020
SOHO 2020
Hodgkin Lymphoma Lymphoma Antibodies Bleomycin Brentuximab vedotin Dacarbazine Doxorubicin Nivolumab Vinblastine

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the latest clinical trials in lymphoma, including an ongoing study evaluating interim PET scans to tailor treatment in stage III/IV disease in addition to an ongoing study evaluating brentuximab vedotin and nivolumab, also in stage III/IV disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Straus

6:38
IVAC +/- rituximab in R/R B-NHLs: a real-world data review
David Straus • 2 Dec 2020
8:50
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial
David Straus • 2 Dec 2020
2:34
R/R lymphoma: checkpoint blockade and transplantation
David Straus • 18 Aug 2020
3:24
Treatment of bulky stage I/II lymphoma
David Straus • 18 Aug 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals